Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ENO1 | P06733 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | OTC | P00480 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.36 |
| ▸ | FNTB | P49356 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421899 | 0.74 | TDP1 (0.40) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL5483953 | 0.73 | — | — | |
| SCHEMBL3229640 | 0.73 | — | — | |
| SCHEMBL13194872 | 0.71 | — | — | |
| SCHEMBL256679 | 0.71 | — | — | |
| SCHEMBL4434279 | 0.71 | — | — | |
| SCHEMBL1380295 | 0.71 | — | — | |
| SCHEMBL1378744 | 0.71 | TDP1 (0.54) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL15137338 | 0.71 | — | — | |
| SCHEMBL26660439 | 0.71 | TDP1 (0.54) | CA12CA1CA2MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| EP-2414332-B1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2414332-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2010114181-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | CA12 3472/4885CA1 3962/4885CA2 2905/4885 |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | CA12 2827/4885CA1 400/4885CA2 76/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | CA12 3472/4885CA1 3962/4885CA2 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.